Nearly all major global biopharmaceutical companies have now agreed to lower the cost of their drugs in the US after reaching most-favoured nation (MFN) pricing deals with the White House — and the few holdouts are expected to make their own agreements next week, President Donald Trump said during a press conference Friday. He made the announcement alongside the leaders of nine companies — Sanofi, Novartis, Roche's Genentech unit, Gilead, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck &

Ipsen said Friday its investigational asset fidrisertib flunked a pivotal mid-stage study in fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone condition, prompting the company to shelve the trial.The Phase II FALKON study enrolled 113 patients aged five years and older with the R206H ACVR1 mutation or other progressive heterotopic ossification (HO)-associated FOP variants to date. Participants were randomised to receive either a high- or low-dose of fidrisertib, or placebo, with an

An investment from the Coalition for Epidemic Preparedness Innovations (CEPI) has breathed new life into Moderna's pandemic influenza vaccine programme, which had been facing an uncertain future since the US government withdrew its support earlier this year. Thanks to a $54.3-million award from CEPI, Moderna will now move its mRNA-based H5 avian influenza vaccine, mRNA-1018, into a Phase III trial.In May, the drugmaker reported positive immunogenicity findings from a Phase I/II trial of the cand

- South Korean biotech company secures US$8 million in upfront payment for the joint commercialization of the stem cell therapy CARTISTEM® targeting the Japanese knee osteoarthritis market. SEOUL, South Korea, Dec. 19, 2025 /PRNewswire/ -- MEDIPOST Co., Ltd. (KOSDAQ 078160), a fully integrated cell therapy biotechnology company, today announced a multi-year partnership with Japan's Teikoku Seiyaku Co., Ltd. for the commercialization of CARTISTEM®, an innovative treatment for knee osteoarthritis

Less than three months after earning an FDA nod for idiopathic pulmonary fibrosis (IPF), Boehringer Ingelheim's Jascayd (nerandomilast) has secured an expanded label to include use in adults with progressive pulmonary fibrosis (PPF).Approval is based on results from the Phase III FIBRONEER-ILD trial, where patients on the oral PDE4B inhibitor experienced a smaller decline in forced vital capacity (FVC) after a year than those receiving placebo, the trial's primary endpoint. Adjusted mean FVC dec

New Delhi: Zydus Lifesciences on Tuesday said its UAE-based unit has inked a licensing pact with Formycon AG for the supply of a cancer treatment biosimilar in the US and Canada. Zydus Lifesciences Global FZE has entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab). Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Globa

REUTERS/Kim Kyung-Hoon/File Photo Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies. More than half the plaque psoriasis patients across the studies showed clear or almost clear skin after 16 weeks of treatment with the once-daily drug, zasocitinib, the company said. Takeda plans to file marketing applications with the U.S. Food and Drug Administration and other regulatory

December 18, 2025 The Wyoming Department of Health (WDH) has identified five cases of measles among Fremont County residents. All five cases are part of the same chain of transmission, with the initial exposures to measles occurring outside the state and potential subsequent spread among close contacts. The five cases include both adults and children. All individuals were unvaccinated at the time of exposure. None were hospitalized. The total number of measles cases reported in Wyoming in 2025 i

Verge intends to use a “leaner cost structure” and continued investment in its technology to scale up its machine learning model, Converge, as a means to achieve profitability.\n After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical asset and returning to its drug discovery roots.The decision comes after VRG50635, the company’s lead asset for amyotrophic lateral sclerosis (ALS), failed a pre-specified efficacy analysi

New Delhi: The Delhi Police has arrested the alleged mastermind of a racket involved in manufacturing and supplying spurious medicines and fake cosmetic products , an official said on Thursday. Pramod Kumar Gupta (67) was arrested from the Hazrat Nizamuddin railway station on December 16. Two other accused - Shree Ram and Gaurav Bhagat - were arrested earlier, DCP (Crime) Aditya Gautam said. Gupta allegedly ran an illegal manufacturing unit, which produced spurious Betnovate-C ointment and fake